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A B S T R A C T
Dynamic flow in vitro models are currently widely explored for their applicability in drug development research.
The application of gut-on-chip models in toxicology is lagging behind. Here we report the application of a gut-
on-chip model for biokinetic studies and compare the observed biokinetics of reference compounds with those
obtained using a conventional static in vitro model. Intestinal epithelial Caco-2 cells were cultured on a porous
membrane assembled between two glass flow chambers for the dynamic model, or on a porous membrane in a
Transwell model. Confocal microscopy, lucifer yellow translocation, and alkaline phosphatase activity evalua-
tion revealed that cells cultured in the gut-on-chip model formed tight, differentiated, polarized monolayers like
in the static cultures. In the dynamic gut-on-chip model the transport of the high permeability compounds
antipyrine, ketoprofen and digoxin was lower (i.e. 4.2-, 2.7- and 1.9-fold respectively) compared to the transport
in the static Transwell model. The transport of the low permeability compound, amoxicillin, was similar in both
the dynamic and static in vitro model. The obtained transport values of the compounds are in line with the
compound Biopharmaceuticals Classification System. It is concluded that the gut-on-chip provides an adequate
model for transport studies of chemicals.
1. Introduction
Toxicological safety studies of pharmaceuticals and industrial che-
micals are an integral part of product development. Traditionally, this
implies the use of animals, which not only is time consuming, con-
sidered unethical and expensive, but importantly also raises scientific
questions related to interspecies differences in biokinetics compared to
humans (Martignoni et al., 2006; Leppert et al., 2006). The combina-
tion of these scientific, socioeconomic, and ethical concerns resulted in
attempts to refine, reduce, or replace (3Rs) the use of animals for tox-
icological safety studies (Matthiessen et al., 2003; Russell and Burch,
1959; Rollin, 2003; Eisenbrand et al., 2002). Since the launch of the 3Rs
principle several in vitro models have been proposed as alternative
models to reduce animal experiments to study drug permeation across
the intestinal epithelium (Kauffman et al., 2013; Guerra et al., 2010;
Cao et al., 2015).
More recently and along these lines, dynamic flow gut-on-chip de-
vices have been proposed as an additional tool to existing static in vitro
cell culture models. The devices mimic in vivo tissue to fluid ratios and
fluid flow by using microfluidic technology (Kim et al., 2012; Kim and
Ingber, 2013) attempting to better recapitulate the in vivo physiological
tissue functioning. An additional advantage of gut-on-chip devices for
compound transport and effect studies is that they allow for integrated
online detection (Gao et al., 2013; Santbergen et al., 2019) and cou-
pling to other organ-on-chip systems (Mahler et al., 2009; Lee et al.,
2017a). Gut-on-chip models have been proposed for preclinical (Chi
et al., 2015; Kim and Ingber, 2013; Kim et al., 2012; Shim et al., 2017)
and pharmacological applications (Gupta et al., 2016; Barata et al.,
2016; Selimovic et al., 2011). To emulate human intestinal disease
models human stem cell-based intestinal models have been used
(Workman et al., 2018). However, given the yet unresolved issues on
reproducibility and lab variability in stem cell models, cell line based
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models are preferred for toxicokinetic and toxicodynamic studies
(Ortmann and Vallier, 2017).
The transport of several compounds has been evaluated using var-
iants of gut-on-chip models, notably: antipyrine, propranolol, naproxen,
furosemide, verapamil, atenolol, piroxicam, hydrochlorothiazide, ci-
metidine, carbamazepine (Yeon and Park, 2009), acetaminophen
(Mahler et al., 2009; Marin et al., 2019; Lee et al., 2017a), rhodamine
123 (Kimura et al., 2008) and curcumin (Gao et al., 2013). Only for a
limited number of compounds the transport in a dynamic gut-on-chip
model has been compared to that in the conventional Transwell model.
These studies have been performed for caffeine, atenolol (Pocock et al.,
2017), cyclophosphamide (Imura et al., 2009), mannitol, insulin (Tan
et al., 2018) acetaminophen (Marin et al., 2019), verapamil, ergotamin
(in)e, food contaminant compounds (Santbergen et al., 2020), and the
environmental contaminants of the dioxin and PCB group (Kulthong
et al., 2018). The observed transport of the compounds in the dynamic
gut-on-chip models were consistent with those obtained using a con-
ventional Transwell for most compounds, with the exception of caffeine
(higher transport in gut-on chip), atenolol (higher transport) and er-
gotaminine (lower transport).
Most gut-on-chip devices are manufactured using poly-
dimethylsiloxane (PDMS). This is mainly because PDMS is biologically
compatible and allows soft lithography-based production methods,
which enable rapid manufacturing of three-dimensional micro-
structures, (McDonald et al., 2000; Thangawng et al., 2007; Tsao,
2016). In addition PDMS-based devices allow microscopy-based read-
outs (Berthier et al., 2012). However, PDMS has a major disadvantage;
it adsorbs a wide range of molecules such as proteins and lipophilic
drugs (Hirama et al., 2019; Berthier et al., 2012; Li et al., 2009). Ad-
sorption can partially be prevented by applying a coating on the PDMS
(van Meer et al., 2017), but this might influence the outcome of a
biological study. Therefore, in our studies we used a microfluidic gut-
on-chip device that consists of three resealable glass slides that, upon
assembly, result in two flow chambers separated by a middle layer that
contains a porous cell culture membrane.
In this study, we aimed to evaluate whether our in vitro gut-on-chip
intestinal barrier model is an adequate model for compound transport
studies. To this end we performed a biokinetic study comparing a dy-
namic gut-on-chip (Kulthong et al., 2018) with a conventionally used
static Transwell model. We exposed Caco-2 cells, grown in the gut-on-
chip or Transwell model to several model compounds for which ex-
tensive information on in vivo bioavailability and transport mechanisms
is available. High and low oral permeability class compounds were
selected, known to represent different absorption mechanisms (e.g.
passive diffusion and active transport). For these drugs we determined
permeability coefficients using both models. In addition, a morpholo-
gical and functional characterization of the dynamic gut-on-chip and
static Transwell models was performed using confocal microscopy and
enzyme activity assays. We report the influence of laminar flow on
compound transport, which was evaluated in the gut-on-chip under
static and dynamic conditions.
2. Materials and methods
2.1. Chemicals and reagents
Antipyrine, ketoprofen, digoxin, amoxicillin, bovine serum albumin
(BSA), Dulbecco's Modified Eagle Medium (DMEM), penicillin-strepto-
mycin, Hank's balanced salt solution (HBSS), trifluoroacetic acid were
obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Phosphate Buffered Saline (PBS), heat inactivated fetal bovine serum
(FBS) and MEM-non-essential amino acids were purchased from Fisher
Scientific (Landsmeer, The Netherlands). Amoxicillin-d4 was obtained
from CacheSyn (Mississauga, Canada). Acetonitrile was obtained from
Biosolve (Valkenswaard, The Netherlands). Formic acid was purchased
form VWR international (Darmstadt, Germany).
2.2. Design of the gut-on-chip system
The microfluidic gut-on-chip device has been described before
(Kulthong et al., 2018). In short, it consists of three 15 × 45 mm (width
× length) re-sealable glass slides that result in two flow chambers (i.e.
an upper apical (AP) and lower basolateral (BL) chamber) upon as-
sembly (see Fig. 1A; Micronit, Enschede, The Netherlands). Both the
Fig. 1. Experimental setup of the gut-on-chip A)
Schematic design of the microfluidic system. B) Flow
velocity simulation of the apical chamber using
COMSOL. A horizontal cross-section was taken in-
dicating a steady value of flow velocity inside the
flowcell, within the laminar regimen. The picture
shows a lower flow speed at the centre of the device.
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upper and lower glass slides were spaced from the middle layer mem-
brane by a 0.25 mm thick silicone gasket and the flow chambers were
separated by a glass slide containing a porous cell culture membrane
that was fixed on the glass slide. The membrane consisted of a polyester
(PET) membrane with a 0.4 μm pore size and a 1 cm2 surface area. The
height of the cell culture area was 0.65 mm and the height of the
bottom flow channel was 0.25 mm, resulting in a volume of 110 mm3
and 75 mm3 for the AP and BL side, respectively, and 185 mm3 for the
total volume of the device (μL). The chip was placed in a chip holder
with a quick locking mechanism, constructed for connection of external
capillaries to the chip via specific ferrules to ensure tight connections
and a leak-free system.
The flow was induced using a multi-channel air pressure driven
pump. Two channels per chip (i.e. one for the AP side and one for the BL
side) were connected to the chip inlets using Polyetheretherketone
(PEEK) capillary tubing (0.125 mm inner diameter, with a total length
of 60 cm). Each flow channel was equipped with a flow sensor to assure
precise regulation of the flow, which was located at 40 cm distance
from the pump and 20 cm distance from the chip. Fluorinated Ethylene
Propylene (FEP) tubing (0.250 nm inner diameter, 40 cm length) was
used to connect to the chip outlets to the culture medium reservoirs.
Before the start of each experiment, all tubing and chips were sterilized
using an autoclave and rinsed with 70% ethanol. Tubing and chips were
prefilled with medium to eliminate air bubbles in the system. The entire
system was put in an incubator at 37 °C to maintain cell culture con-
ditions.
2.3. Cell culture
A Caco-2 cell line (HTB-37), derived from a human colorectal ade-
nocarcinoma, was obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were grown (at passage number
29–45) in complete culture medium, consisting of DMEM supplemented
with 10% FBS, 1% penicillin-streptomycin, and 1% MEM non-essential
amino acid, further referred to as DMEM+.
The cells were seeded at a density of 75,000 cells per cm2 on 12-well
Transwell polyester inserts (0.4 μm pore size, 1.12 cm2 surface area,
Corning Amsterdam, The Netherlands) and cultured in DMEM+ for
21 days. The medium was changed every two to three days.
In the microfluidic chip, the cells were seeded at a density of 75,000
cell per cm2 and were allowed to attach to the membrane. After 24 h the
membrane was inserted in the microfluidic chip. After attachment, the
cells were exposed to a continuous flow of 100 μL/h DMEM+ for
21 days. By doing so, the shear stress in the AP compartment was
~0.0002 dyn/cm2 at the membrane surface, where the cells are grown.
The DMEM+ medium contained sodium bicarbonate (10 mM) to opti-
mize the pH buffering capacity.
2.4. Caco-2 monolayer integrity
Apical to basal translocation of lucifer yellow was measured in a
Caco-2 monolayer under static and dynamic conditions. A lucifer
yellow solution of 500 μg/mL in DMEM+ was perfused through the
apical channel of the chip with a flow rate of 100 μL/h. The basolateral
channel was perfused with DMEM+ with a flow rate of 100 μL/h.
Sample aliquots of 50 μL were collected from the apical and basal outlet
every half hour for 3 h. The same concentration of lucifer yellow so-
lution was added apically to the cells in a Transwell (500 μL/insert) and
incubated for 1 h before collecting the medium sample from the apical
and basolateral chambers. The fluorescence intensity (485/530 nm) of
all collected samples from both systems was measured using a micro-
plate reader (Synergy HT, BioTek, VT).
2.5. Fluorescent imaging of in vitro epithelial cell morphology
Twenty-one days after seeding, Caco-2 cells, grown in the gut-on-
chip or Transwell, were prepared for cell and monolayer morphological
assessment. The chips were opened, and cells were fixed with 4% for-
maldehyde at room temperature for 10 min and rinsed with PBS. Cells
were then permeabilized with 0.25% Triton X100 in PBS for 10 min,
rinsed with PBS and blocked with 1% acetylated bovine serum albumin
in PBS for 30 min. Tight junctions were stained with 10 μg/mL con-
jugated antibody ZO-1/TJP1-Alexa Fluor 594 (Invitrogen, Waltham,
MA). The nuclei were stained with 5 μg/mL DAPI (Invitrogen,
Waltham, MA) and 4 U/mL Phalloidin Alexa Fluor 488 (Life technol-
ogies, Carlsbad, CA) was used to stain actin filaments (i.e. cytoskeleton).
The incubation time for all stainings was 30 min. Each membrane was
then cut out and placed between two cover slips separated by a spacer
(0.12 mm depth × 20 mm diameter) with a drop of anti-fading
mounting medium on the membrane. The cells cultured on Transwell
membranes were stained using the same procedure. The stained
monolayers of cells were analysed using a confocal microscope (LSM
510 UVMETA; Carl Zeiss, Germany). Samples were excited with 405,
488 and 543 nm lasers. Multi-tracked images were captured to avoid
bleed through. The used pinholes were in the range of 148–152 μm at a
magnification of 40×. The gain and offset for the different channels
were kept constant during the entire experiment.
2.6. Caco-2 differentiation
Alkaline phosphatase (ALP) activity was measured in cells cultured
for 21 days in both systems using an ALP colorimetric assay kit
(ab83369, Abcam, Cambridge, UK) following the protocol of the man-
ufacturer. Briefly, the membranes/inserts were taken from the chip/
Transwell chambers. After washing the cells with HBSS at 37 °C,
trypsin/EDTA was added to the cells and they were incubated for
5–7 min. The cell suspension was collected and centrifuged at 300g for
5 min at 4 °C. The cell pellet was then resuspended in 200 μL ALP assay
buffer and centrifuged at maximum speed, 16,000 RPM for 5 min at
4 °C. The supernatant (sample) was then collected and pipetted into the
well of a 96-wells plate before adding the reaction buffer (50 μL/well),
containing a p-nitrophenyl Phosphate solution (5 mM). After the plate
was incubated in the dark for 60 min at 25 °C, 20 μL stop solution was
added to each well of the reaction and shaken gently. Absorbance was
read immediately at 405 nm using a microplate reader. A standard
curve of p-nitrophenol (pNP) was prepared in a concentration range of
0–20 nmol/well, and converted to concentration after blank subtrac-
tion. Enzyme activity was calculated and expressed as nmol of pNP/min
and normalised to the total amount of cells in term of protein content,
which was measured using a RC-DC assay, a colorimetric protein de-
termination based on the principle of Lowry estimation.
2.7. Computational model to calculate shear stress
Computational fluid dynamics was used to calculate the wall shear
stress of the cell culture medium in the gut-on-chip using COMSOL
Multiphysics® v. 5.3 (www.comsol.com, COMSOLAB, Stockholm,
Sweden). The microfluidic device consisted of two rectangular micro-
chambers separated by a glass middle layer containing a PET mem-
brane. The inner dimensions of the rectangular chamber used for si-
mulation consisted of one inlet and one outlet, the maximum inner high
was 0.25 mm, the maximum width was 11 mm and length from inlet to
outlet was 30 mm, and an oval cavity at the centre with area of 1.0 cm2.
Considering a steady flowrate of 100 μL/h we obtained laminar flow
conditions with a Reynolds number of 0.007. The culture medium was
considered as an incompressible and homogeneous, Newtonian fluid
with similar conditions to water at 37 °C (density; 997 kg/m3 and
viscosity; 6.9 × 10−4 Pa s−1). A laminar Flow/Stationary library was
used to determine the shear rate. The shear stress was estimated by
multiplying the shear rate with the dynamic viscosity of water at 37 °C.
An extremely coarse mesh size was used to reduce the computing time.
No-slip boundary conditions were applied to the microchannel walls.
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Since the flow cell is fully made of glass, it was considered rigid with
impermeable walls. The shear stress was obtained from the simulation
using the height of 0.25 mm (near the inlet) and another position with
an additional height of 0.40 mm at the centre of the chamber on the
PET membrane. To corroborate this COMSOL calculation we used an
adapted Poiseuille equation for rectangular microchannels as a second
method (Zhang et al., 2014; Pocock et al., 2017). This equation could be
applied to our system since the microfluidic chamber width is larger
than the height (h < <w). To calculate the shear stress using this
method two different heights were taken in consideration: 1) from the
top to the glass middle layer (0.25 mm), and 2) from the top to the PET
membrane (0.65 mm). Comparison of the COMSOL simulation and the
adapted Poiseuille equation showed equal results.
2.8. Caco-2 viability
Cytotoxicity was assessed using an MTT assay, a mitochondrial ac-
tivity-based cell viability assay. Caco-2 cells (50,000 cells/cm2) were
seeded in 96-well plates. After 24 h, the medium was discarded and was
subsequently replaced with various concentrations of antipyrine (0, 25,
50, 100, 250 or 500 μM), ketoprofen (0, 25, 50, 100, 250 or 300 μM),
digoxin (0, 25, 50, 100, 125 or 250 μM), or amoxicillin (0, 25, 50, 100,
250 or 500 μM) in HBSS for 24 h. At the end of the treatment period,
cells were washed with 100 μL PBS, and 60 μL of 0.8 mg/mL MTT
solution in DMEM+ was added to the cells and further incubated for
1.5 h. The medium was then discarded, and the cells were permeabi-
lized resulting in formazan crystals dissolving in 100 μL of DMSO. The
absorbance was measured at 570 using a microplate reader and the
background absorbance at 650 nm was subtracted. The percentage of
cell viability was calculated from the absorbance obtained from the
control divided by that of each treatment.
2.9. Compound transport studies across a monolayer of intestinal Caco-2
cells
The transport studies were performed following an established
protocol for static transport studies using Caco-2 cells (Hubatsch et al.,
2007). At day 21 post-seeding, a non-toxic concentration of 100 μM
antipyrine, 100 μM ketoprofen, 125 μM digoxin, and 250 μM amox-
icillin was prepared in a transport medium (HBSS).
In the gut-on-chip studies, each compound solution was perfused
through the upper channel with a flow rate of 100 μL/h, whereas 4%
BSA in HBSS was pumped through the basolateral channel. An aliquot
(100 μL) was collected from the apical and basolateral outlet every hour
for six hours.
In the Transwell studies, the cells were washed with HBSS for
15–20 min at 37 ͦ C (0.5 mL in apical side, and 1.5 mL in basolateral
side). Subsequently, HBSS was removed from the basolateral chamber
and replaced with 1.2 mL basolateral medium (4% BSA in HBSS).
Compound solutions of 0.4 mL in HBSS were then added to the apical
side of the inserts. From the basolateral side, aliquots (600 μL) were
collected and replaced with the same volume of 4% BSA in HBSS at
settled time points (0, 15, 30, 60, 90 and 120 min for antipyrine, ke-
toprofen and digoxin, and 0, 30, 60, 90, 120, 150 and 180 min for
amoxicillin). All the liquid from the apical and basolateral chamber was
collected at the last time point in order to calculate a mass balance. All
samples were stored in −80 °C before analysis.
The transport was calculated from the experimental data using Eq.
(1) for the Transwell data and (2) for the gut-on-chip data. Eq. (2) was
derived from Eq. (1) (Yeon and Park, 2009).
⎜ ⎟= ⎛
⎝
⎞
⎠
⎛
⎝
⎞
⎠
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0 (1)
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Where A is the surface area (cm2), dQ is the amount of the model
compound transported (μmol) over the respective time interval, dt (s),
C0 is the initial concentration (μM), C is the concentration in the ba-
solateral compartment (μM), and V is the flow rate (L/s).
2.10. Sample quantification (HPLC-UV/LC-MS/MS)
All samples from the transport experiments, except for the amox-
icillin samples from experiments with cell monolayer in both models,
were analysed using high-performance liquid chromatography (HPLC),
as described previously (Li et al., 2013), to quantify the amount of
compound in the sample. Prior to analysis, one volume of collected
sample was mixed with ACN or MeOH for amoxicillin to precipitate the
BSA. After centrifugation at 16000g for 10 min, the supernatant was
injected in the HPLC column for analysis. Antipyrine and ketoprofen
samples (50 μL) were applied to a C18 reverse-phase column
(150 mm × 4.6 I.D, 5 μm particle size) with a guard column
(7.5 mm × 4.6 mm I.D.; Alltech, The Netherlands) and detected by a
UV detector (Perkin-Elmer, Waltham, MA) at 260 (antipyrine) and 254
(ketoprofen) nm. Digoxin (100 μL) and amoxicillin (50 μL) samples
were injected to the same column and was detected and quantified by
UV absorption (Waters, Milford, MA) at 220 and 245 nm, respectively.
Trifluoroacetic acid (TFA) 1% in water (solvent A) and ACN (solvent B)
were used as the mobile phase for analysis of all test compounds. For
analysis of antipyrine, ketoprofen and amoxicillin, elution was applied
at a flow rate of 1.0 mL/min, starting at 90% solvent A with a linear
decrease to 0% solvent A in 20 min. Then, the gradient returned to the
initial concentration in 2 min, which was maintained for 10 min before
the next sample was injected. For the analysis of digoxin, the gradient
elution started with 78% solvent A at a flow rate of 0.7 mL/min for
2 min, followed by a linear decrease to 0% solvent A in 8 min. Then, the
gradient returned to the initial conditions by a linear gradient over
2 min and remained at this condition for 10 min. Calibration curves
were made using commercially available reference compounds for each
individual set of samples to enable quantification of the obtained re-
sults.
In the case of the amoxicillin studies with cells, liquid chromato-
graphy–mass spectrometry (LC-MS), was used to detect the amount of
amoxicillin in the samples. Briefly, a 250 μL aliquot of the basolateral
Transwell samples or 25 μL of gut-on-chip samples and apical Transwell
samples was mixed with 10 μL of internal standard working solution
(25 μg/L AMOX-d4). Then, 2 mL of ACN was added and the solution
was placed in a rotary tumbler for 15 min followed by centrifugation at
3500g for 10 min. After that, ACN was evaporated with N2 at 40 °C and
the remaining pellet was re-suspended with either 100 μL 25 (v/v)%
MeOH for the basolateral Transwell samples or 200 μL for the baso-
lateral gut-on-chip samples. For the apical samples, evaporation was
not necessary because of their higher concentrations. For all samples
100 μL was diluted with 900 μL 25% MeOH, and transferred to LC-MS/
MS vials. Five μL of the sample was injected into the Acquity liquid
chromatographic separation system (Waters, Milford, MA,) through an
Acquity UPLC HSS T3 column (2.1 mm × 100 mm I.D., 1.8 μm)
(Waters) at 30 °C employed under the gradient mixture of 0.001 (v/v)%
formic acid in water (A) and 0.001 (v/v)% formic acid in ACN (B) at a
flow rate of 0.4 mL/min. The gradient program was as follows: 0–1 min
0% B; 1–2.5 min, from 0 to 25% B; 2.5–5.4 min, from 25 to 70% B;
5.4–5.5 min, from 70 to 100% B; 5.5–8.5 min, 100% B; 8.5–8.6 min,
from 100 to 0% B; followed by the re-equilibration at 0% B for 0.9 min
before the next injection. The LC eluent was introduced directly into the
electrospray ionization source (ESI) of the Q-Trap6500 mass spectro-
meter (Sciex, Framingham, MA) operating in the negative mode.
Nitrogen was used as nebulizing turbo spray gas. The operational
parameters of the ESI turbo ion source were as follows: vaporizing
temperature 450 °C; curtain gas 35; and ionspray voltage −4000 V.
Compound fragmentation was achieved using collision induced dis-
sociation using N2 as collision gas. The following multiple reaction
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monitoring (MRM) transitions were used; the precursor ion [M- + H]-
+ for amoxicillin was measured at m/z 363.9 and the corresponding
product ions were measured at m/z 222.9 and m/z 206. The diclus-
tering potential (DP) was set at −15 V and the collision energy (CE)
was−14 V and−24 V, respectively. The precursor ion [M- + H]-+ for
amoxicillin-d4 was measured at m/z 367.9 and the product ion was m/z
227.0. The DP was −45 V, and CE was −14 V. Data processing was
carried out using Multiquant software V3.0.2 (Sciex, Framingham, MA).
For quantification, the peak areas of the target ions were corrected with
those of the internal standard and the concentrations were determined
using a matrix matched calibration line.
2.11. Statistical analysis
All statistical evaluations were evaluated using an independent
paired t-test (SPSS, IBM). A p-value of ≤0.05 was considered sig-
nificant.
3. Results
3.1. Simulated shear stress in the microfluidic gut-on-chip device
For the gut-on-chip experiments, the chip was placed in a chip
holder connected to an eight-channel pump system (for four chips) with
a flow sensor for every channel, allowing precise control of the apical
(AP) and basolateral (BL) flow (Fig. 1A). Computational fluid dynamics
were used to calculate and visualize the shear stress and flow velocity
changes over the geometry of the microfluidic device. As can be seen in
Fig. 1B, the flow velocity is highest near the inlet and decreases as the
microchannels broaden until their maximal width (11 mm). In addition,
due to an increment in the height of the chamber, the flow velocity was
the lowest at the centre of the chamber. The shear stress at the cell
culture surface area was calculated at ~0.0002–0.0017 dyn/cm2.
3.2. Caco-2 cell monolayer integrity
Caco-2 cells were grown on the membrane in both the gut-on-chip
and the Transwell model. Lucifer yellow was used as a fluorescent
marker to monitor the integrity of the tight junctions between the Caco-
2 cells. As shown in Fig. 2 the paracellular permeability value (Papp) of
lucifer yellow decreased in time in both tested systems. Both systems
demonstrated a tight monolayer after ~9 days of culture, but the Papp in
the gut-on-chip appeared to fluctuate more in the first week of culture.
After 9 days of culture, the permeability of lucifer yellow was stable and
not significantly different between both systems (1.10 × 10−6,
0.76 × 10−6, 0.40 × 10−6 for the Transwell at day 9, 11, 15 and
0.72 × 10−6, 0.54 × 10−6, 0.64 × 10−6 cm/s for the gut-on-chip at
day 9, 11, 14;P > .05; Independent t-test).
3.3. Assessment of cellular morphology
Caco-2 cells were cultured under continuous flow or static condi-
tions for 21 days, in a gut-on-chip or Transwell, respectively. The cel-
lular morphology was analysed using confocal microscopy, and re-
presentative images are shown in Fig. 3. Caco-2 cells grown under both
conditions formed a comparable pattern of tight junctions, indicating
monolayer formation, at day 5 to day 21 (Fig. 3A and B). By creating Z-
stacks vertical cross-sections of the monolayers were assessed (Fig. 3C
and D). Visual inspection showed an increase in the height of the
monolayers in time in both systems, reaching ~10 μm at day 21.
Marked differences between both culture systems became apparent in
the subcellular localization of actin filaments after ~11 days of cul-
turing. Monolayers grown under static conditions mainly expressed
actin at the apical side, but cells grown under dynamic conditions ex-
hibited more pronounced actin filaments located along the entire height
of the cells including the basolateral side of the cells, were the cells
were attached to the supporting porous membrane (Fig. 3E and F).
3.4. Caco-2 cell differentiation
The functional development of the cells in both the gut-on-chip and
Transwell model was assessed by determining the ALP activity of the
cells. ALP activity is an established marker of epithelial cell differ-
entiation (Zucco et al., 2005; Jumarie and Malo, 1994; Ferruzza et al.,
2012). The ALP activity of the cells grown under both conditions are
shown in Fig. 4. Cells grown in the gut-on-chip system showed an in-
crease in ALP activity in time, albeit with some fluctuations. At day 21,
the ALP activity reached 15.2 ± 5.5 nmol/mg protein/min. Cells
grown under static conditions also exhibited an increase in ALP activity
in time, reaching 11.4 ± 4.5 nmol/mg protein/min. There were no
significant differences in cellular ALP activity between the Caco-2 cells
grown in the Transwell and gut-on-chip system at each individual time
point (P > .05; Independent t-test).
3.5. Selection of non-cytotoxic concentrations of drugs
The MTT assay was used to select non-toxic concentrations of
compounds to be applied in the subsequent transport studies.
Proliferating (1 day old) cells were exposed to concentrations up to
500 μM, 300 μM, 250 μM and 500 μM of antipyrine, ketoprofen, di-
goxin, and amoxicillin, respectively, for 24 h. As shown in Fig. 5, no
cytotoxicity (> 80% viability) was observed for all compounds at the
highest tested concentrations.
3.6. Comparative drug transport under static and dynamic flow conditions
Compound translocation studies across Caco-2 cell monolayers
Fig. 2. Time dependent Papp (apparent permeability constant) reflecting tight junction integrity of a Caco-2 cell monolayer determined by measuring the paracellular
translocation of lucifer yellow in a Transwell system A), and a gut-on-chip system B). The values are presented as means± SEM; n= 3 and 7 (Transwell and gut-on-
chip).
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grown under dynamic (gut-on-chip) and static (Transwell) conditions
were performed 21 days after seeding of the cells. The transport of the
compounds, antipyrine, ketoprofen, digoxin and amoxicillin, was de-
termined using HPLC or LC-MS. A recovery of 83–118% for all mea-
surements indicated little loss of compounds due to non-specific
binding to the hardware or chemical instability.
The transport of the highly translocated compounds; antipyrine,
ketoprofen, and digoxin was significantly lower in the gut-on-chip
(Papp = 5.4 × 10−6, 5.9 × 10−6 and 8.8 × 10−6 cm/s; p < .05) than
in the Transwell (Papp = 22.7 × 10−6, 16.0 × 10−6 and 16.4 × 10−6
cm/s) (Fig. 6A-C, and Table 1). Whereas the transport of the lowly
translocated compound, amoxicillin appeared slightly higher in the gut-
on-chip (Papp = 5.8 × 10−7 cm/s) versus the Transwell
(Papp = 1.1 × 10−7 cm/s), although this difference was not significant
(p > .05) (Fig. 6D and Table 1). To examine the influence of solely the
system (i.e. Transwell vs. gut-on-chip) on the transport behaviour of the
Fig. 3. Morphology of Caco-2 cells cultured for 21 days in a static Transwell system or in a gut-on-chip system under a continuous flow of 100 μL/h, visualized by
confocal microscopy. Top views of the cell layer showing comparable tight junction patterns (ZO-1/TJP1) in red over a culture period of 21 days in A) a Transwell
and in B) a gut-on-chip. Vertical cross-sections of the cell monolayer showing actin filaments (Phalloidin) in green, cell nuclei (DAPI) in blue, and tight junctions (ZO-
1/TJP1) in red in C) a Transwell and D) a gut-on-chip. Note the increase in actin filaments over the entire cell height in the gut-on-chip versus the Transwell.
Horizontal cross-sections at the basolateral side of the cells in E) a Transwell and F) a gut-on-chip further demonstrate the pronounced basolateral presence of actin
(Phalloidin; green) in the Transwell versus gut-on-chip. The scale bar represents 10 μm. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
Fig. 4. ALP activity in Caco-2 cells grown in Transwell A) or gut-on-chip B). The values are presented as means± SEM; n = 3 and 4 for Transwell and gut-on-chip,
respectively.
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compounds, both Transwell and gut-on-chip were also exposed to the
compounds without cells.
Diffusion (expressed as Papp) of all four compounds across the
membranes in both the gut-on-chip under dynamic conditions and
Transwell (static conditions) without Caco-2 cell monolayers was sig-
nificantly lower under dynamic flow in the gut-on-chip compared to the
Transwell (i.e. four to seven-fold lower) (Fig. 6). Antipyrine and keto-
profen tested without cells showed translocation values that were
Fig. 5. Cell viability of 1-day old Caco-2 cells exposed for 24 h to increasing concentrations of A) antipyrine, B) ketoprofen, C) digoxin, and D) amoxicillin, given as a
percentage (± SEM) of the negative control (n = 4).
Fig. 6. Apparent permeability (Papp) values (± SEM) of model compounds; A) antipyrine, B) ketoprofen, C) digoxin, and D) amoxicillin under static Transwell (open
bare), or dynamic gut-on-chip (gray bar) conditions, with or without 21-day old Caco-2 cells cultured on the porous membrane.* significant difference compared with
the static Transwell (p < .05); # significant difference compared with the without cells condition (p < .05); (n= 3; antipyrine, digoxin, and amoxicillin); (n = 5;
ketoprofen in gut-on-chip system).
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comparable to those obtained in the experiments with cells; antipyrine
(Transwell; Papp = 24.8 × 10−6 cm/s, gut-on-chip;
Papp = 6.0 × 10−6) and ketoprofen (Transwell; Papp = 18.8 × 10−6
cm/s, gut-on-chip; Papp = 4.7 × 10−6 cm/s). The transport of digoxin
through the membrane without cells was also comparable with the
transport through the membrane with cells in the Transwell
(Papp = 19.1 × 10−6 cm/s). In the gut-on-chip the transport of digoxin
was significantly lower without cells (Papp = 2.8 × 10−6 cm/s).
Amoxicillin showed an increased translocation through the membrane
without cells in both the Transwell and gut-on-chip (Transwell;
Papp = 19.3 × 10−6 cm/s, gut-on-chip; Papp = 3.7 × 10−6 cm/s).
As the diffusion of the four compounds in the gut-on-chip system
under dynamic conditions was lower than in the Transwell system as
demonstrated by our experiments without the Caco-2 monolayers, the
influence of the liquid flow in the gut-on-chip on the transport of an-
tipyrine was examined. For this we examined the transport of anti-
pyrine in gut-on-chip with cells, with or without flow. Without the flow,
antipyrine showed a two-fold increased transport (Papp = 10.4 × 10−6
cm/s) compared to the transport with the flow (Papp = 5.4 × 10−6 cm/
s), but the transport was still two-fold lower than in the Transwell
system (Papp = 22.7 × 10−6 cm/s) (Fig. 7). The transport of all four
compounds was also tested in the gut-on-chip and Transwell system
without cells and without flow, showing approximately 2-fold lower
Papp values for all compounds in the gut-on-chip system (Suppl.
Table 1).
4. Discussion
We aimed to evaluate whether our in vitro gut-on-chip intestinal
barrier model is an adequate model for compound translocation studies.
For this, we performed a biokinetic study comparing our dynamic gut-
on-chip (Kulthong et al., 2018) with a conventional model using the
static Transwell model. In both systems comparable trends in com-
pound specific Papp values were observed. However, we observed
marked differences in absolute transport rates in the Transwell versus
the gut-on-chip model that most likely were caused by differences in
experimental conditions and the design and intrinsic characteristics of
the microfluidic chip.
In this study we used glass two-chamber microfluidic chips sepa-
rated by a PET membrane on which we cultured epithelial cells (Caco-
2) under dynamic conditions. Using a largely glass based microfluidic
chip avoids the often raised issue of compound binding to PDMS based
chips (van Meer et al., 2017). We successfully observed a high recovery
of compounds as we have also shown previously for highly lipophilic
compounds (Kulthong et al., 2018) indicating that no compounds were
lost in the total chip setup, that includes tubing with a relatively large
surface area.
To perform biokinetic studies, conventionally Caco-2 cells are used
after 21 days of culturing in Transwell systems, when they have de-
veloped into a tight monolayer of differentiated cells (Artursson et al.,
2001). We assessed the cell layer integrity in the conventional Trans-
well model versus the gut-on-chip model by exposing monolayers of
cells to a marker for paracellular transport (lucifer yellow). The para-
cellular translocation dropped quickly for the Caco-2 monolayers in the
Transwell model reaching stable low levels in the second week of cul-
turing. A similar trend, albeit more variable, was observed for the Caco-
2 monolayers grown under dynamic flow conditions in the chip. Pre-
viously, other research groups have characterized Caco-2 cell layer
integrity and differentiation in microfluidic chips, but in chips with
different designs. Using microfluidic chips with a narrow long channel,
full maturation of the cell monolayer and barrier integrity was observed
already after 3–5 days of seeding (Kim et al., 2012; Chi et al., 2015),
which is faster than observed in our model. Next we evaluated the
differentiation of the Caco-2 cells in both the gut-on-chip and Transwell
by determining ALP activity, a known marker for intestinal cell dif-
ferentiation (Jumarie and Malo, 1994; Ferruzza et al., 2012; Zucco
et al., 2005). Caco-2 cell differentiation was comparable in both sys-
tems, ALP activity increased upon increasing the culture period with a
maximum activity reached on day 21. Again, in a chip with a narrow
elongated channel, it was observed that brush border aminopeptidase
activity already on day 3-5 reached the same level as following 21 days
of culturing in Transwell (Kim et al., 2012, Chi et al., 2015). Due to the
differences in chip design the resulting shear stress experienced by the
Table 1
Overview of the apparent permeability values (Papp) (± SEM) of the selected compounds in Caco2-cells cultured under static (Transwell) and dynamic (gut-on-chip)
conditions in this study, and in vitro and in vivo Papp values or ranges (obtained from literature).
Compound Papp (×10−6 cm/s) Literature in vitro Transwell Papp (×10−6cm/s) Human in vivo Papp (×10−6cm/s) BSC class Fa (%)
Transwell Gut-on-chip
Antipyrine 22.7 ± 0.5 5.4 ± 0.2 11.3–150.0a 560d Id 100d
Ketoprofen 16.0 ± 1.6 5.9 ± 0.4 10.5–93.0a 870d Id 100d
Digoxin 16.4 ± 0.7 8.8 ± 0.1 0.59–4.69b N/A IIe 75f
Amoxicillin 0.11 ± 0.02 0.58 ± 0.2 0.021–1.8c 30d IIId 45-75d
BCS: Biopharmaceutics Classification System. Class I and II: high permeability, class III: low permeability.
Fa: human absorption of compounds.
a Data obtained from (Lee et al., 2017b).
b Data obtained from (Djnv and Nilsen, 2008; Elsby et al., 2008).
c Data obtained from (Jung et al., 2006; Irvine et al., 1999; Gres et al., 1998).
d Data obtained from (Lennernas, 2014).
e Data obtained from (Wu and Benet, 2005).
f Data obtained from (Takenaka et al., 2016). N/A: not available in vivo literature.
Fig. 7. Apparent permeability (Papp) values (± SEM) of antipyrine in the gut-
on-chip system with 21-day old Caco-2 cells, under dynamic (with flow), or
under static (without flow) conditions.* significant difference compared with
dynamic conditions (p < .05); (n = 3).
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cells is different in this chip system as compared to ours. In our device,
we estimated a shear stress of approximately 0.0002–0.0017 dyn/cm2
which is lower compared to the 0.02 dyn/cm2 reported for the channel
chips (Kim et al., 2012). Literature data on in vivo shear stress in the gut
however report highly variable ranges, between ~0.002–12.0 dyn/cm2
(Kim et al., 2012; Guo et al., 2000; Hardacre et al., 2016), depending on
the intestinal location and viscosity of digesta. Therefore, to mimic the
real shear stress experience by epithelial cells within the intestinal
lumen is still challenging in vitro. Lastly, we have evaluated the
monolayer morphology of Caco-2 cells grown in the gut-on-chip and
static Transwell using confocal microscopy. While the cell height was
comparable, cells grown under constant flow expressed more actin fi-
laments on the basolateral side compared to cells grown under static
conditions, as shown before (Kulthong et al., 2018). Actin filaments are
associated with cell adhesion and mechanics, remodelling of actin fi-
laments might alter cell spread, migration, elongation, or enlargement
of the cells (Noria et al., 2004; Miura et al., 2015). The remodelling of
the actin filaments did not affect the barrier integrity in the gut-on-chip
model.
We exposed differentiated monolayers of Caco-2 cells, grown under
dynamic flow conditions in the gut-on-chip and under static conditions
in the Transwell system, to four model compounds representing high
and low permeability compound classes (Biopharmaceuticals
Classification System (BCS). Monolayers of differentiated Caco-2 cells
are regarded representative for the gastrointestinal absorption of
compounds in vivo with the best correlation for drugs transported by the
passive transcellular route (Cheng et al., 2008; Artursson et al., 2001).
The highly transported compounds antipyrine, ketoprofen and digoxin
indeed showed high Papp values in both systems. Amoxicillin, a low
transported compound, showed low Papp values in both systems. The
Papp values derived from the static experiment were in line with those
previously obtained from static in vitro Caco-2 experiments for anti-
pyrine, ketoprofen and amoxicillin (see Table 1 and references therein).
Our digoxin Papp value was higher, in both the Transwell and gut-on-
chip system than those reported before. This difference likely can be
explained by the variable expression of P-glycoprotein 1 by Caco-2
cells, this efflux transporter is responsible for the cellular excretion of
digoxin. Variable expression levels can depend on the passage number
of the cultured cells (Goto et al., 2003). The Papp values of the high
permeability (class I) compounds antipyrine and ketoprofen were about
4.2 and 2.7 folds lower, respectively, when evaluated using Caco-2 cells
under dynamic flow conditions in the gut-on-chip compared to Caco-2
cells under static conditions in Transwell. Given the outcome of our
experiments without cells and without flow, we conclude that these
differences can be explained by (laminar) flow related effects and by
influence of the design of the chip and/or the material of the membrane
on diffusion of these compounds. Laminar flow is the fluid flow that
occurs in long thin parallel layers with no disruption between them and
can be defined by the Reynolds number. The Reynolds number is the
ratio of internal force to viscous force. For our gut-on-chip conditions
the Reynolds number equals ~0.007. At low Reynolds numbers, viscous
forces dominate, which implies a low migration (or diffusion) of dis-
solved chemicals across layers resulting in less contact of the com-
pounds with the cell surface (Sosa-Hernandez et al., 2018;
Christoffersson, 2018). In the absence of flow, diffusion is facilitated,
this is demonstrated by the ~2 times higher Papp value of antipyrine in
the gut-on-chip with cells without flow versus with flow. Nevertheless,
the Papp value in the gut-on-chip with cells and without flow was still
lower than that in the Transwell. The use of different membranes and
the influence of different designs (i.e. apical and basolateral volumes) in
the gut-on-chip and Transwell models could have contributed to these
observed differences as shown by static experiments using both mem-
branes.
Monolayers of Caco-2 cells, are a standard model used to categorize
drugs into the four classes of the Biopharmaceuticals Classification
System (BCS) and to predict intestinal absorption of compounds
(Smetanova et al., 2011; Miret et al., 2004). However, in the literature
reported (apparent) permeability values of compounds in vitro vary
between labs and are lower than those reported for human in vivo
(Table 1). The latter usually is explained by the higher TEER values in
vitro compared to TEER values in vivo (Lennernas, 1998; Lee et al.,
2017b; Artursson et al., 2001). Therefore, relative correlation values
between in vitro and human data have been often used to evaluate the
prediction potential of new in vitro models and to predict whether ab-
sorption of compounds in human will be high or low (Irvine et al.,
1999; Li et al., 2007; Marino et al., 2005; Takenaka et al., 2016). The
transport data in our study are consistent with the BCS compound
classification, showing higher transport of antipyrine, ketoprofen, and
digoxin than amoxicillin.
Compound translocation of the four model compounds in the gut-
on-chip and Transwell are in line with the compound
Biopharmaceuticals Classification System, albeit absolute Papp values of
class I and II compounds were markedly lower in the gut-on-chip.
Clearly the laminar fluid flow in the microfluidic chip affects the
transport of compounds, by limiting the diffusions of compounds to-
wards the membrane. A solution can be to incorporate herringbone-
shaped groves to allow mixing as shown by (de Haan et al., 2019).
Secondly, the shape of the cell compartment affects the shear force and
liquid flow patterns. The consequences of these design characteristics,
and thus accompanying shear forces, on cell morphology, cell phy-
siology, and cell differentiation and on how this affects compound
transport still needs to be assessed. Comparative studies on monolayer
morphology related to chip design are emerging (Bein et al., 2018).
In conclusion, different Papp values of the tested compounds were
obtained in the gut-on-chip and Transwell models for antipyrine, ke-
toprofen, and digoxin. The Papp value obtained for the low permeability
compound amoxicillin was comparable in both models. These results
are in line with the compound Biopharmaceuticals Classification
System. Thus, both the gut-on-chip and the Transwell model can be
used for transport studies of chemicals. The gut-on-chip model allows
for integration with on line detection of compounds (Santbergen et al.,
2020) while the classical static Transwell model is easier to use.
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